First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia

Share :
Published: 12 Jun 2015
Views: 2294
Rating:
Save
Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany

Dr Ehninger presents on the results of a phase II randomised study on the safety and efficacy of sorafenib in leukaemia at a press conference at EHA 2015.

Read the news story for more.